Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
The Pineal Gland01:02

The Pineal Gland

The pineal gland, a diminutive endocrine structure named for its pinecone-shaped appearance, is situated atop the third ventricle within the diencephalon region of the forebrain. This gland, composed of secretory cells known as pinealocytes arranged in compact cords and clusters around dense particles of calcium salts, plays a pivotal role in hormonal regulation.
The primary secretion of the pineal gland is the hormone melatonin, derived from serotonin. The concentration of melatonin in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Face-straight-down and face-near-straight-down positions in healthy, prone-sleeping infants.

The Journal of pediatrics·1996
Same author

Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less.

The Journal of pediatrics·1996
Same author

[Human babesiosis in a patient after splenectomy].

Medicina clinica·1996
Same author

Checkpoints in the progression of autoimmune disease: lessons from diabetes models.

Proceedings of the National Academy of Sciences of the United States of America·1996
Same author

Effect of in vivo activation of natural killer (NK) cells by a tilorone analogue on the survival of mice injected intravenously with different experimental murine tumours.

Clinical and experimental immunology·1996
Same author

Transmission of hepatitis C virus by a cardiac surgeon.

The New England journal of medicine·1996

Related Experiment Video

Updated: Jun 27, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Melatonin as a selective estrogen enzyme modulator.

S Cos1, A González, C Martínez-Campa

  • 1Department of Physiology and Pharmacology, School of Medicine, University of Cantabria, Santander, Spain. coss@unican.es

Current Cancer Drug Targets
|December 17, 2008
PubMed
Summary
This summary is machine-generated.

Melatonin inhibits breast cancer growth by affecting estrogen pathways. This indoleamine acts as a selective estrogen receptor modulator (SERM) and selective estrogen enzyme modulator (SEEM), offering potential as an anticancer drug.

More Related Videos

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
09:07

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay

Published on: December 19, 2018

Related Experiment Videos

Last Updated: Jun 27, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay
06:07

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
09:07

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay

Published on: December 19, 2018

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Melatonin demonstrates oncostatic properties against various tumors, particularly hormone-dependent breast cancer.
  • In vivo studies show melatonin reduces mammary tumor incidence and growth in rodents.
  • In vitro research indicates melatonin inhibits human breast cancer cell proliferation and invasiveness.

Purpose of the Study:

  • To investigate the mechanisms by which melatonin inhibits breast cancer growth.
  • To explore melatonin's interaction with estrogen-signaling pathways in breast cancer.
  • To evaluate melatonin's potential as a therapeutic agent for estrogen-dependent mammary tumors.

Main Methods:

  • In vivo studies using chemically-induced mammary tumors in rodents.
  • In vitro experiments with human breast cancer cells.
  • Analysis of melatonin's effects on estrogen receptor activation and estrogen-metabolizing enzymes.

Main Results:

  • Melatonin inhibits breast cancer cell proliferation and invasiveness.
  • Melatonin modulates estrogen signaling through indirect neuroendocrine mechanisms, direct receptor interaction (SERM), and enzyme regulation (SEEM).
  • Melatonin reduces aromatase, sulfatase, and 17beta-hydroxysteroid dehydrogenase activity while increasing estrogen sulfotransferase, thereby protecting mammary tissue.

Conclusions:

  • Melatonin exhibits both SERM and SEEM properties, aligning with desired characteristics for breast cancer therapeutics.
  • Melatonin's multifaceted action on estrogen biosynthesis and signaling pathways makes it a promising anticancer agent.
  • Melatonin holds potential for the prevention and treatment of estrogen-dependent mammary tumors.